These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 26529070)
41. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Treanor JJ; Essink B; Hull S; Reed S; Izikson R; Patriarca P; Goldenthal KL; Kohberger R; Dunkle LM Vaccine; 2013 Nov; 31(48):5760-5. PubMed ID: 24075920 [TBL] [Abstract][Full Text] [Related]
42. Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults. Rivera L; Mazara S; Vargas M; Fragapane E; Casula D; Groth N Vaccine; 2012 Jul; 30(35):5285-92. PubMed ID: 22659448 [TBL] [Abstract][Full Text] [Related]
43. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330 [TBL] [Abstract][Full Text] [Related]
44. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847 [TBL] [Abstract][Full Text] [Related]
45. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. DiazGranados CA; Dunning AJ; Jordanov E; Landolfi V; Denis M; Talbot HK Vaccine; 2013 Jan; 31(6):861-6. PubMed ID: 23261045 [TBL] [Abstract][Full Text] [Related]
46. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803 [TBL] [Abstract][Full Text] [Related]
47. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258 [TBL] [Abstract][Full Text] [Related]
48. Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults. Yang LP Drugs; 2013 Aug; 73(12):1357-66. PubMed ID: 23928902 [TBL] [Abstract][Full Text] [Related]
50. Ontology-Based Vaccine Adverse Event Representation and Analysis. Xie J; He Y Adv Exp Med Biol; 2017; 1028():89-103. PubMed ID: 29058218 [TBL] [Abstract][Full Text] [Related]
51. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study. Stuurman AL; Verstraeten T; De Schryver A Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801 [TBL] [Abstract][Full Text] [Related]
52. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Cox MM; Izikson R; Post P; Dunkle L Ther Adv Vaccines; 2015 Jul; 3(4):97-108. PubMed ID: 26478817 [TBL] [Abstract][Full Text] [Related]
53. Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study. Hsiao A; Hansen J; Nunley KV; Lewis N; Selmani A; Inamdar A; Mallett-Moore T; Izikson R; Rudin D; Klein NP Vaccine; 2022 Jan; 40(5):774-779. PubMed ID: 34998605 [TBL] [Abstract][Full Text] [Related]
54. Influenza vaccine for 2019-2020. Med Lett Drugs Ther; 2019 Oct; 61(1583):161-166. PubMed ID: 31770355 [No Abstract] [Full Text] [Related]
55. [Safety data of the new, reduced-dose influenza vaccine FluArt after its first season on the market]. Vajó P; Gyurján O; Szabó ÁM; Kalabay L; Vajó Z; Torzsa P Orv Hetil; 2017 Dec; 158(49):1953-1959. PubMed ID: 29199437 [TBL] [Abstract][Full Text] [Related]
56. Influenza vaccine for 2021-2022. Med Lett Drugs Ther; 2021 Oct; 63(1634):153-157. PubMed ID: 34550956 [No Abstract] [Full Text] [Related]
59. In response to: scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Effler P; Kelly HA Vaccine; 2013 Aug; 31(35):3467-8. PubMed ID: 23632308 [No Abstract] [Full Text] [Related]